Of the 50,000 people in the United States who are diagnosed with kidney cancer each year, 90% have renal cell carcinoma (RCC). Standard cancer treatment such as chemotherapy and radiation generally are ineffective when treating kidney tumors. MD Anderson Cancer Center is conducting new research to determine the best drug sequence for fighting this disease. Nizar Tannir, M.D., associate professor in the Genitourinary Medical Oncology department, discusses his kidney cancer clinical trial, Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy (the START trial), as well as provides facts about the disease.

Loading the Audio Player...

Title: Kidney Cancer – Basic Facts and New Research – CNLSummary: Of the 50,000 people in the United States who are diagnosed with kidney cancer each year, 90% have renal cell carcinoma (RCC). Standard cancer treatment such as chemotherapy and radiation generally are ineffective when treating kidney tumors. MD Anderson Cancer Center is conducting new research to determine the best drug sequence for fighting this disease. Nizar Tannir, M.D., associate professor in the Genitourinary Medical Oncology department, discusses his kidney cancer clinical trial, Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy (the START trial), as well as provides facts about the disease.Keywords: Cancer Newsline, CNL, Kidney, cancer, nizar tannir, start, clinical trial, Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy, researchTranscript: